AKEEGA

• tagApproval8 co-mentions · 2 sources
• drugabiraterone acetate4 co-mentions · 2 sources
• companyJanssen Biotech Inc4 co-mentions · 2 sources
• tagSmall Molecule4 co-mentions · 2 sources
• drug(abiraterone acetate + niraparib)4 co-mentions · 2 sources
• drugYonsa4 co-mentions · 2 sources

Trials studying AKEEGA

• phase1A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Canceractive not recruitingn=136
• phase1A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Canceractive not recruitingn=57
• phase1M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)active not recruitingn=60
• phase3A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancerrecruitingn=750
• phase2Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.recruitingn=192
• phase2A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancerrecruitingn=100
• phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)recruitingn=1,314
• phase2A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Canceractive not recruitingn=136